SM-04554 | 1360540-81-3

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: SM-04554
• 英文别名: 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenylbutane-1,4-dione；1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-phenylbutane-1,4-dione
• CAS: 1360540-81-3
• 化学式: C₁₈H₁₆O₄
• 分子量: 296.323
• InChiKey: AOCDRSSVFUCURK-UHFFFAOYSA-N

物化性质

• 沸点：
  500.1±50.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO:80.0(最大浓度 mg/mL);270.0(最大浓度 mM)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 储存条件：
  -20°C

制备方法与用途

Wnt pathway activator 1 是一种有效的 Wnt 激活剂，其 IC50 值为 28-29 nM，更多信息可参见专利 WO2012024404A1 中的化合物 1。

反应信息

• 作为产物：
  描述：

  1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(dimethylamino)propan-1-one 、 苯甲醛 在 3-乙基-5-(2-羟乙基)-4-甲基噻唑溴化物 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 以12%的产率得到SM-04554
  参考文献：
  名称：

  BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS

  摘要：

  本发明公开了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的β-二酮、γ-二酮或γ-羟基酮或其类似物，例如骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、与中枢神经系统的分化和发育相关的创伤性脑损伤，包括帕金森病、中风、缺血性脑血管疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；眼部疾病，如年龄相关性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性，以及与干细胞分化和生长相关的疾病，包括脱发、造血相关疾病和组织再生相关疾病。

  公开号：

  US20120046320A1

文献信息

• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20140243349A1

  公开（公告）日：2014-08-28

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本公开提供了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的γ-二酮或其类似物；这些疾病包括骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、创伤性脑损伤或脊柱损伤、与中枢神经系统分化和发育相关的脑萎缩/神经系统疾病，包括帕金森病、中风、缺血性脑疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；耳部疾病如耳蜗毛细胞丧失；眼部疾病如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性以及与干细胞分化和生长相关的疾病，如脱发、造血相关疾病和组织再生相关疾病。
• RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICONE HAVING ONIUM GROUP
  申请人：Shibayama Wataru

  公开号：US20110143149A1

  公开（公告）日：2011-06-16

  There is provided a resist underlayer film forming composition for lithography for forming a resist underlayer film capable of being used as a hard mask or a bottom anti-reflective coating, or a resist underlayer film causing no intermixing with a resist and having a dry etching rate higher than that of the resist. A film forming composition comprising a silane compound having an onium group, wherein the silane compound having an onium group is a hydrolyzable organosilane having, in a molecule thereof, an onium group, a hydrolysis product thereof, or a hydrolysis-condensation product thereof. The composition uses as a resist underlayer film forming composition for lithography. A composition comprising a silane compound having an onium group, and a silane compound having no onium group, wherein the silane compound having an onium group exists in the whole silane compound at a ratio of less than 1% by mol, for example 0.01 to 0.95% by mol. The hydrolyzable organosilane may be a compound of Formula: R 1 a R 2 b Si(R 3 ) 4-(a+b) . A resist underlayer film obtained by applying the composition as claimed in any one of claims 1 to 14 onto a semiconductor substrate and by baking the composition.

  提供一种用于光刻的抗蚀底层膜形成组合物，用于形成可用作硬掩膜或底部防反射涂层的抗蚀底层膜，或者是不与抗蚀剂混合且具有比抗蚀剂更高的干法刻蚀速率的抗蚀底层膜。该组合物包括具有离子基的硅烷化合物，其中具有离子基的硅烷化合物是一种可水解的有机硅烷，其分子中具有一个离子基、其水解产物或水解缩合产物。该组合物用作光刻的抗蚀底层膜形成组合物。组合物包括具有离子基的硅烷化合物和不具有离子基的硅烷化合物，其中具有离子基的硅烷化合物在整个硅烷化合物中的摩尔比例小于1％，例如为0.01到0.95％。可水解的有机硅烷可以是式的化合物：R1aR2bSi（R3）4-（a+b）。通过将所述组合物按照权利要求1至14中的任一项涂布到半导体基片上并烘烤所得到的抗蚀底层膜。
• RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING ANION GROUP
  申请人：Shibayama Wataru

  公开号：US20110287369A1

  公开（公告）日：2011-11-24

  There is provided a resist underlayer film forming composition for lithography for forming a resist underlayer film capable of being used as a hardmask. A resist underlayer film forming composition for lithography comprising a silane compound containing an anion group, wherein the silane compound containing an anion group is a hydrolyzable organosilane in which an organic group containing an anion group is bonded to a silicon atom and the anion group forms a salt structure, a hydrolysis product thereof, or a hydrolysis-condensation product thereof. The anion group may be a carboxylic acid anion, a phenolate anion, a sulfonic acid anion, or a phosphonic acid anion. The hydrolyzable organosilane may be a compound of Formula (1): R 1 a R 2 b Si(R 3 ) 4−(a+b) (1). A composition comprising a mixture of a hydrolyzable organosilane of Formula (1), and at least one organic silicon compound selected from the group consisting of a compound of Formula (2): R 4 a Si(R 5 ) 4−a (2) and a compound of Formula (3): [R 6 c Si(R 7 ) 3−c ] 2 Y b (3); a hydrolysis product of the mixture; or a hydrolysis-condensation product of the mixture.

  提供了一种用于光刻的抗蚀底层膜形成组合物，用于形成可用作硬膜的抗蚀底层膜。该抗蚀底层膜形成组合物包括含有阴离子基团的硅烷化合物，其中含有阴离子基团的硅烷化合物是一种可水解的有机硅烷，其中含有阴离子基团的有机基团与硅原子键合，阴离子基团形成盐结构，其水解产物或水解缩合产物。阴离子基团可以是羧酸阴离子、酚酸盐阴离子、磺酸盐阴离子或磷酸盐阴离子。可水解的有机硅烷可以是式（1）的化合物：R1aR2bSi（R3）4−（a+b）（1）。组合物包括式（1）的可水解有机硅烷的混合物，以及选择自化合物组中的至少一种有机硅化合物的混合物，该组具有式（2）的化合物：R4aSi（R5）4−a（2）和式（3）的化合物：[R6cSi（R7）3−c] 2Yb（3）；该混合物的水解产物；或该混合物的水解缩合产物。
• B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20140080902A1

  公开（公告）日：2014-03-20

  The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本发明揭示了β-二酮、γ-二酮或γ-羟基酮或其类似物，其激活Wnt/β-连环蛋白信号传导，从而治疗或预防与信号传导相关的疾病，如骨质疏松症和骨关节病；成骨不全症、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颜部缺陷、肿瘤溶解性骨病、与中枢神经系统分化和发育相关的创伤性脑损伤，包括帕金森病、中风、缺血性脑病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；眼部疾病，如年龄相关性黄斑变性、糖尿病性黄斑水肿或色素性视网膜炎以及与干细胞分化和生长相关的疾病，包括脱发、造血相关疾病和组织再生相关疾病。
• β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
  申请人：KC Sunil Kumar

  公开号：US08609717B2

  公开（公告）日：2013-12-17

  The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本发明公开了β-二酮、γ-二酮或γ-羟基酮或其类似物，其激活Wnt/β-连环蛋白信号传导，因此可治疗或预防与信号转导相关的疾病，如骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、创伤愈合、颅面缺陷、骨溶解性疾病、与中枢神经系统分化和发育相关的创伤性脑损伤，包括帕金森病、中风、缺血性脑病、癫痫、阿尔茨海默病、抑郁症、躁郁症和精神分裂症；眼疾病，如年龄相关性黄斑变性、糖尿病黄斑水肿或色素性视网膜炎，以及与干细胞分化和生长相关的疾病，包括脱发、造血相关疾病和组织再生相关疾病。